Current filters:

NovartisBiogen Idec

1 to 9 of 47 results

Multiple sclerosis treatments funding proposal in New Zealand

Multiple sclerosis treatments funding proposal in New Zealand


New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving…

Biogen IdecFinancialGilenyaNeurologicalNew ZealandNovartisPharmaceuticalTysabri

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI


This year’s American Society of Hematology (ASH) meeting continued yesterday with more clinical trial…

Biogen IdecEloctateHematologyJakaviNovartisPharmaceuticalResearchSobiTakeda PharmaceuticalsUSA

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs


More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Multiple sclerosis market could reach $18.3 billion in 2018


The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

News briefs from Sanofi, Biogen/SOBI and Novartis


French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch


The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients


In the USA, 77% of surveyed neurologists have experience with the STRATIFY JCV assay - commercially available…

AvonexBiogen IdecElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalTysabri

1 to 9 of 47 results



Back to top